← Ablatotech Signals
RareDisease SignalsArticle

A putative therapeutic target in cystic fibrosis CFTR modulator: P35998

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
August 19, 2026 · Lead editor: RareDiseaseEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — P35998 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in cystic fibrosis CFTR modulator.

Background

The protein encoded by the gene associated with UniProt accession P35998 is a putative target that warrants experimental validation as a potential modulator for cystic fibrosis (CF). Cystic fibrosis is a rare genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to severe respiratory and digestive issues. The therapeutic potential of targeting CFTR modulators is significant, as they aim to enhance the function of the defective CFTR protein in affected individuals.

Data-mining rationale

The rationale for identifying P35998 as a candidate for cystic fibrosis CFTR modulation stems from a comprehensive cross-referencing of UniProt's reviewed human entries related to cystic fibrosis against microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Notably, P35998 has been detected in expression-profiling studies; however, it lacks any registered Phase 1 or higher clinical programs, indicating a gap in its exploration as a therapeutic target.

Why prior analyses may have missed this

Many of the GEO datasets that include expression data relevant to P35998 predate the adoption of modern empirical-Bayes statistical methods, such as limma. These earlier analyses may not have adequately accounted for multiple-testing corrections, potentially leading to overlooked or misinterpreted signals. Re-analysis of these datasets using contemporary statistical approaches could yield new insights into the expression patterns and relevance of P35998 in the context of cystic fibrosis.

Reasoning for further validation

To substantiate the potential of P35998 as a CFTR modulator, several experimental approaches are suggested:

  1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of less than 0.05 to identify differentially expressed genes accurately.
  2. Validate the top differentially expressed genes through quantitative PCR (qPCR) in an independent cohort to confirm expression changes.
  3. Investigate tissue specificity of P35998 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to understand its relevance in cystic fibrosis-affected tissues.
  4. Utilize pathway analysis tools like STRING and OmniPath to explore the biological context and interactions of P35998 within cellular pathways.
  5. If validation is achieved, assess the druggability of P35998 through databases such as DGIdb and ChEMBL to evaluate its potential as a therapeutic target.

© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications